+29%

est. 2Y upside i

HealthcareIPO

Rank

#2904

Sector

Biotechnology

Est. Liquidity

~2Y

Data Quality

Data: High

BridgeBio presents a moderate upside opportunity for a job seeker over a two-year horizon, with an estimated 28.5% expected return.

Last updated: March 10, 2026

Bull (21%)+100%

BridgeBio successfully navigates the tafamidis IP trial, and Attruby continues its strong market penetration, reaching over $1.5B in annual revenue by 2028. Additionally, infigratinib, BBP-418, and encaleret gain regulatory approvals and launch successfully, contributing significantly to revenue and pushing the company to sustained profitability with an EPS of over $1.50 by 2028, justifying a $25B+ valuation.

Base (46%)+45%

Attruby maintains its strong growth trajectory, reaching approximately $1.2B in annual revenue by 2028, and one or two pipeline assets (e.g., infigratinib or BBP-418) secure approval and begin commercialization. The company achieves modest profitability with an EPS around $0.60 by 2028, leading to a valuation of around $18B.

Bear (33%)-40%

The tafamidis IP trial results in an unfavorable outcome, significantly impacting Attruby's market share and pricing power. Pipeline assets face unexpected regulatory delays or commercial challenges, and high R&D costs persist, leading to continued heavy losses beyond 2028. Revenue growth stalls, and the valuation drops to $7.5B or lower, significantly eroding common stock value.

Est. time to liquidity~2.0 years

Preference Stack Risk

moderate

Funding Intensity

3%

Investors hold $1.684 billion in funding, representing a moderate preference stack of 13.26% relative to the current $12.7 billion valuation.

Dilution Risk

high

Ongoing heavy losses and high cash burn could necessitate further funding rounds, potentially diluting existing shareholders, despite current cash reserves of over $1 billion.

Secondary Liquidity

active

As a publicly traded company on NASDAQ (BBIO), there is active secondary market liquidity for equity.

Other — 70 roles

View all 70 open roles at BridgeBio →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on BridgeBio's data — designed to show you've done your homework.

  • 1

    “Given the strong launch of Attruby and positive Phase 3 results for infigratinib, BBP-418, and encaleret, how is BridgeBio prioritizing its commercialization efforts and resource allocation across these potentially transformative therapies, especially considering the high incumbent threat from Pfizer and BioMarin?”

  • 2

    “BridgeBio has demonstrated remarkable revenue growth but continues to incur heavy losses. What is the company's strategic roadmap to achieve profitability within the next 3-5 years, and how will the anticipated 'flat to declining' R&D spend and 'materialally cheaper' future launches contribute to this goal?”

  • 3

    “With a current valuation of $12.7B and a moderate preference stack, what are the company's expectations for future funding needs, potential dilution, and the timeline for significant liquidity events or sustained stock price appreciation for employees over the next two years?”

Community

Valuation Sentiment

Our model estimates +29% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.